M. Baccarani

New England Journal of Medicine · 2002–2020

A researcher in the Science corpus: 17 papers; trusts 0 researchers and is trusted by 1 researcher here, as inferred from the citation graph.

Whom M. Baccarani trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. J. Apperley
2. Brian J. Druker
3. H. Kantarjian
4. Andreas Hochhaus
5. J. Cortes

Who trusts M. Baccarani overall

1. J. Cortes
2. Brian J. Druker
3. Andreas Hochhaus
4. J. Apperley
5. H. Kantarjian

Papers from M. Baccarani's perspective

Ordered by how strongly the researchers M. Baccarani trusts endorse each paper. Same corpus, a different order for every researcher.

1. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (Journal of Clinical Oncology)
2. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. (Cancer Cell)
3. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. (The Lancet Oncology)
4. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. (Blood)
5. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. (Journal of Clinical Oncology)
6. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
7. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase… (Blood)
8. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (Blood)
9. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
10. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. (Blood)

Their papers

• Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. (2010) — 821 citations
• European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia (2020) — 1,281 citations
• Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia (2017) — 1,052 citations
• Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial (2016) — 852 citations
• A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias (2013) — 1,031 citations
• European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. (2013) — 1,917 citations
• Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). (2012) — 612 citations
• Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. (2010) — 722 citations
• Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (2009) — 1,280 citations
• Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients (2007) — 685 citations
• Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. (2007) — 616 citations
• Chronic myeloid leukaemia. (2007) — 792 citations
• Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (2006) — 1,349 citations
• Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. (2006) — 3,470 citations
• Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. (2003) — 3,629 citations
• Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. (2002) — 1,073 citations
• Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. (2002) — 2,100 citations